U.S.-German genetic testing specialist Qiagen reported better-than-expected quarterly earnings on Tuesday, citing very strong demand for COVID-19 testing combined with improvements in non-COVID-19 areas of its portfolio.
Qiagen said fourth-quarter net sales rose 36% to $571.2 million on a currency-adjusted basis, beating the $539.14 million expected on average by analysts in a Vara Research poll, as improved trends for its QuantiFERON tuberculosis test, cancer diagnostics and DNA sample technologies complemented coronavirus-related sales.
The company confirmed its guidance for 2021 adjusted EPS and net sales growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.